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Abstract
BACKGROUND: Various risk scoring methods are available to predict the severity of coronary artery disease (CAD). 
However, the majority of them are complex and require advanced technologies, thus limiting its usage in primary care 
settings. CHA2DS2-VASc-HSF is a novel risk scoring which we develop from CHA2DS2-VASc score.
AIM: We hypothesize that CHA2DS2-VASc-HSF is predictive for the risk of severe CAD, and we compare its validity 
with previously established CHADS2 and CHA2DS2-VASc score.
MATERIALS AND METHODS: A total of 210 patients who underwent elective coronary angiography were enrolled in 
our study. Anthropometric, laboratory, angiographic findings, and patient history were obtained from medical records 
and used to calculate CHA2DS2-VASc-HSF score. Severe CAD defined as coronary artery occlusion with the Gensini 
score of ≥20. Statistical analyses were done using SPSS 25.0 and MedCalc 18.2.1.
RESULTS: This research showed that the patient with severe CAD has significantly higher CHADS2, CHA2DS2-
VASc, and CHA2DS2-VASc-HSF score compared to normal and mild CAD (p < 0.001). CHADS2, CHA2DS2-VASc, 
and CHA2DS2-VASc-HSF correlated significantly with the CAD severity (r = 0.315, p ≤ 0.001; r = 0.395, p ≤ 0.001; 
r = 0.612, p ≤ 0.001, respectively). CHA2DS2-VASc-HSF may predict the risk of severe CAD independent from 
other variables (odds ratio = 2.540; 95% confidence interval = 1.794–3.595; p = 0.002) with the cutoff value of 
≥2.5 (sensitivity = 81.4% and specificity = 68.1%). Pairwise comparison of receiver operating characteristic curves 
showed that CHA2DS2-VASc-HSF was superior to predict severe CAD.
CONCLUSIONS: CHA2DS2-VASc-HSF scores may predict the risk of severe CAD better than CHADS2 and 
CHA2DS2-VASc score. This score may easily be used in primary care physicians to predict the risk of severe CAD 
and provide an early referral to the cardiologist.
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Introduction
Coronary artery disease (CAD) remained the 
top cause of mortality and morbidity for a person aged 
35 and over worldwide [1], [2]. Failure to detect CAD 
and provide early treatment may cause CAD treatment 
to become a more expensive and higher mortality 
rate [2]. It is estimated that around one-third of the 
middle age’s population in the USA will suffer from CAD 
manifestation [3]. In Indonesia, the Indonesian Ministry 
of Health also showed that CAD is the leading cause of 
morbidity, which is responsible for 12.9% of death [4].
Determining the best risk factor assessment 
for CAD is extremely important for early prevention and 
treatment. The screening for CAD using angiography is 
easily available in developed countries with short waiting 
lists. However, in developing countries, the awareness 
and accessibility of cardiovascular disease screening 
are still low [5]. To obtain cost-effective prevention and 
treatment of CAD at the patient level, stratification of the 
cardiovascular risk using a simple method is extremely 
important. Cardiovascular risk screening will have a 
relevant implication for decision making in early referral 
and healthcare resource allocation [6].
At present, CHADS2 and CHA2DS2-VASc 
scores have been established as clinical predictors 
for cardiac thromboembolism and indication of 
antithrombotic therapy [7]. Both CHADS2 and CHA2DS2-
VASc component has similarities with the risk factors 
of CAD development [8]. The components within the 
CHADS2 score also had been proven in large cohort 
studies to be associated with CAD in with ischemic 
stroke patients [9], while CHA2DS2-VASc is the 
refinement of CHADS2 score, which has been proven to 
outperform its predecessor in the various patient group, 
including AF patient who received elective electrical 
cardioversion [10]. This suggests CHA2DS2-VASc 
score may predict the risk for both cerebrovascular and 
cardiovascular diseases. However, these scores did not 
include the major risk factors of CAD such as smoking, 
hyperlipidemia, and family histories. Hence, this 
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research aims to improve the validity of the CHA2DS2-
VASc score by including new major risk factor of CAD 
which are hyperlipidemia (H), smoking (S), and family 
history of CAD (F) and compare it with the previous 
CHADS2 and CHA2DS2-VASc score to predict severe 
CAD in the patients.
Materials and Methods
Study design
This cross-sectional study involves 210 
consecutive patients who underwent coronary 
angiography in the Cardiology Department of Ramelan 
Navy Hospital Surabaya during 1 year period between 
January-December 2018. Coronary artery occlusion 
was assessed from angiograms using the Gensini 
score. Patients with infectious processes within 
2 weeks before catheterization, hepatic dysfunction, 
thyroid dysfunction, cancer, and chronic kidney disease 
were excluded from the study. This study had received 
ethical clearance (No.06/EC/KERS/2019) from the local 
ethics committee. Informed consents were obtained and 
details which disclose patients’ identity were omitted.
Risk factor data collection
Clinical findings, 12-lead electrocardiogram, 
and echocardiographic examination were performed 
based on the American Society of Echocardiography 
guidelines [11]. The standard laboratory was performed 
to measure fasting blood glucose (FBG), total 
cholesterol, and renal function tests from the blood 
samples [12].
CHA2DS2-VASc-HSF score consists of 
congestive cardiac failure (C), hypertension (H), age 
>75 years (A), diabetes mellitus (D), stroke (S), vascular 
diseases (V), age 65–74 years (A), sex category (Sc), 
hyperlipidemia (H), smoking (S), and family history of 
cardiovascular disease (F) were obtained by medical 
record thorough examination. Congestive cardiac 
failure (C) score was given if left ventricular ejection 
fraction was reduced (<45%) from echocardiography 
examination. Hypertension (H) was defined as systolic 
blood pressure >140 mmHg or diastolic <90 mmHg 
for repeated measurement, or when the patient was 
taking antihypertensive medications. Diabetes mellitus 
(D) Type 2 was defined FBG >126 mg/dl, previous 
diabetes diagnosis, or when the patient was taking 
anti-diabetic medications. Stroke (S) was defined 
as the history or current diagnosis of stroke or TIA 
which was given by the patients. Vascular disease 
(V) was defined from the existence of a pathologic 
condition which causes stenosis of at least 50% in the 
non-coronary artery. Hyperlipidemia (H) defined as 
a cholesterol level of more than 200 mg/dL based on 
the National Cholesterol Education Program or when 
the patient is consuming of lipid-lowering medications. 
Cigarette smoking (S) was defined as the habit of 
smoking of more than five cigarettes per-day without a 
quit attempt for a minimum of 1 year. Family history of 
cardiovascular disease (F) was defined as the presence 
of cardiovascular disease or sudden cardiac-related 
death of the first degree-relative.
CHA2DS2-VASc-HSF scoring
CHA2DS2 score was calculated by adding 
1 point for the presence of chronic heart failure, age 
>75 years, DM and hypertension by assigning 2 points 
for the history of stroke or TIA. In the CHA2DS2-VASc 
score, age 65–74 was assigned for 1 point (A) and 
age >75 years (A2) was assigned for 2 points. The 
CHA2DS2-VASc-HSF score put 1 point for the finding 
of hyperlipidemia (h), smoking (S), and family history of 
the cardiac disease (F).
Coronary angiography and Gensini 
scoring
Judkins technique 4 with 5-F catheters was 
used to perform cannulation of coronary arteries. Kodak 
35-mm cinefilm was used to record the images at 30 
frames⁄s. Computer-assisted coronary angiography 
analysis system was used to detect coronary stenosis 
(Mipron 1; Kontron, Tokyo, Japan). One minute after 
the injection of ISDN (2.5 mg/5 mL for 20 s) through 
the Judkins catheter, several projections were taken 
to observe the coronary angiography. Coronary 
atherosclerosis severity was measured using the 
Gensini scoring method, as described previously [12].
Calculation of the Gensini score was done for 
each patient through the severity score assignment 
based on coronary occlusion. Narrowing between 1 
and 25% will be scored 1, 26–50% will be scored 2, 
51–75% will be scored 3, 75–90% will be scored 8, 
91–99% will be scored 16, and 100% will be scored 32. 
The score is then multiplied based on the location and 
importance of the artery. We multiply by factor 5 for left 
main coronary artery occlusion, 2.5 for both proximal 
circumflex artery and proximal left anterior descending 
artery, 1.5 for a mid-left anterior descending artery, and 
1 mid or distal circumflex artery, for distal left anterior 
descending artery and the right coronary artery. The 
multiplication factor for any other branch is 0.5 [3].
Statistical analyses
Data analyses were performed using SPSS 
Statistics 25.0 and MedCalc 18.2.1. Continuous 
variables, presented as mean ± standard deviation (SD), 
were compared using ANOVA test. Correlation between 
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parametric variables was obtained using Spearman’s Rho 
followed by logistic regression. Specificity and sensitivity 
were obtained from the receiver operating characteristic 
(ROC) curve and cutoff point analysis. Area under the 
curve (AUC) comparison was done using the pairwise 
comparison method as described previously [13].
Results
Clinical characteristics of the patients
The total of 210 patients was involved in this 
study. Table/Figure 1 shows the characteristics of the 
participant, which grouped based on the CAD severity. 
Of the 210 patients, 70 patients had normal angiogram 
(Gensini score = 0, 33.3%), 48 patient had mild CAD 
(Gensini score = 1–19, 22.9%), and 92 patients had 
obstructive/severe CAD (Gensini score >20, 43.8%). 
The comparison of the baseline demographics and 
characteristics of the three groups (normal coronary 
arteries, mild CAD, and severe CAD) is presented in 
Table 1.
From Table 1, significant differences between 
severe CAD and normal angiography groups were 
observed on the age, FBG, ureum, and creatinine 
which are the CAD risk factors. CHADS2, CHA2DS2-
VASc, and CHA2DS2-VASc-HSF score also significantly 
higher on the patient with severe CAD compared to the 
patient with normal angiography.
Correlations between multiple variables 
with CAD severity
The correlation test was used to identify the 
factors associated with the severity of CAD. Table 2 
shows the results of Spearman’s correlations between 
Gensini score and multiple independent variables in the 
in subjects. Spearman’s correlation analysis showed that 
the highest correlation was identified on the CHA2DS2-
VASc-HSF score with Gensini score, which showed a 
moderate to strong correlation (r = 0.612, p = ≤ 0.001).
Logistic linear regression analysis of the 
variables to predict severe CAD
Univariate and multivariate logistic linear 
regression analysis was done on various variables in 
predicting the outcome (severe CAD) as presented 
in Tables 3 and 4. The analysis from Tables 3 and 4 
showed that CHADS2, CHA2DS2-VASc, and CHA2DS2-
VASc-HSF were significant predictors for severe CAD.
Specificity and sensitivity test using ROC 
curves
From the ROC curves in Figure 1, it is 
suggested that CHA2DS2-VASc-HSF score has higher 
AUC compared to CHADS2 and CHA2DS2-VASc 
score. Optimum cutoff point analysis showed that the 
CHA2DS2-VASc-HSF score ≥2.5 provided the highest 
predictive value for severe CAD (sensitivity = 81.4% and 
specificity = 68.1%). Pairwise comparison from Table 5 
showed that the CHA2DS2-VASc-HSF score was found 
to be the best scoring scheme to predict severe CAD 
compared to CHADS2 and CHA2DS2-VASc score.
Figure 1: Receiver operating characteristic curve of CHADS2, 
CHA2DS2-VASc, and CHA2DS2-VASc-HSF score to predict severe 
CAD. AUC: Area under the curve; CI: Confidence interval
Table 1: Characteristics of the patients based on CAD severity
Variables* CAD severity p-value
Normal angiogram (n=70) Mild CAD (n=48) Severe CAD (n=92)
Age (years) 50.97 ± 8.95b,c 53.87 ± 10.90a 54.65 ±9.13a ≤0.001
SBP (mmHg) 131.81 ± 26.17 123.00 ± 16.67 130.90 ± 23.05 0.691
DBP (mmHg) 72.81 ± 10.86 76.53 ± 9.12 77.58 ± 9.23 0.463
Weight (kg) 69.48 ± 12.43 65.27 ± 7.70 70.03 ± 9.88 0.369
Height (m) 164.06 ± 8.59 164.33 ± 3.90 165.45 ± 5.79 0.208
BMI (kg/m2) 25.67 ± 3.26 24.22 ± 3.28 25.55 ± 3.15 0.341
Hb (g/dL) 14.01 ± 1.11 13.63 ± 1.73 14.60 ± 3.75 0.474
WBC (cells/µL) 7434.2 ± 1725.5 6746.0 ± 1624.1 7350.1 ± 2108.5 0.292
HCT (%) 41.63 ± 3.64 41.20 ± 4.89 42.46 ± 4.36 0.897
Platelet (×103 cells/µL) 273.00 ± 78.55 271.66 ± 47.73 258.12 ± 52.97 0.268
PT (s) 13.31 ± 1.28 13.56 ± 2.67 13.56 ± 3.46 0.301
APTT (s) 32.56 ± 3.23 31.33 ± 6.19 33.39 ± 5.27 0.097
FBG (mg/dL) 108.06 ± 37.97c 114.13 ± 32.82 112.45 ± 34.39a 0.032
Ureum (mg/dL) 12.45 ± 3.15b,c 16.81 ± 5.20a 16.45 ± 7.70a 0.005
Creatinine (mg/dL) 1.00 ± 0.31b,c 1.27 ± 0.25a 1.16 ± 0.26a 0.005
Ejection fraction (%) 57.65 ± 18.31 64.73 ± 5.96 52.15 ± 16.85 0.474
CHADS2 Score 0.68 ± 0.65
b,c 0.60 ± 0.99a 1.08 ± 0.94a ≤0.001
CHA2DS2-VASc Score 1.32 ± 0.83
b,c 1.47 ± 1.06a 1.95 ± 1.04a ≤0.001
CHA2DS2-VASc-HSF Score 2.06 ± 0.77
b,c 2.33 ± 1.23a,c 3.43 ± 1.20a,b ≤0.001
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index, Hb: Hemoglobin; WBC: White blood cells; HCT: Hematocrit; PT: Prothrombin time; APTT: Activated partial thromboplastin time; FBG: Fasting 
blood glucose; SD: Standard deviation. Values are presented as a mean±SD; different annotation showed a significant difference (p<0.05) for the post hoc LSD test to normal angiogram (a), mild CAD (b) and severe CAD (c).
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The severe CAD may be fatal if remained 
undiagnosed and developed further into coronary 
total occlusion, which caused myocardial infarction. 
Hence, early detection of severe CAD is extremely 
important to prevent the mortality and morbidity of 
the patients [3]. Coronary angiography is the gold 
standard to diagnose the severity of stable CAD. 
However, early coronary angiography screening is 
lacking in developing countries [14]. Hence, clinicians 
need reliable, simple, objective, and quantitative 
tools to identify these risk stratifications to refer the 
patient for early screening, modify the risk factor, and 
provide early treatment [15]. Several scoring systems 
which involve major risk factors such as European 
SCORE and Framingham risk score (FRS) have been 
developed to assess the risk of CAD [16]. FRS is the 
most widely used score, which estimates the 10-year 
risk of developing CAD risk. However, this score 
cannot assess the severity of CAD. Furthermore, FRS 
also overestimates cardiovascular mortality rates in a 
low-risk population and underestimates it at the high-
risk populations [17], [18]. Due to its multiplicity and 
complexity, FRS, SCORE, and other scoring systems 
are considered to be unpractical for daily use for primary 
care physician [19], [20]. Hence, alternatives scoring 
such as that CHADS2, CHA2DS2-VASc, and CHA2DS2-
VASc-HSF may offer a better alternative, which is easily 
be applied by the physician without any additional cost.
This study showed that CHADS2, CHA2DS2-
VASc, and CHA2DS2-VASc-HSF are having a positive 
and significant correlation with CAD severity measured 
by Gensini score. The highest correlation was found on 
the CHA2DS2-VASc-HSF score. This was in accordance 
with the previous research that showed both CHADS2 and 
CHA2DS2-VASc score are significantly correlated with 
the Gensini score with almost similar r-value (r = 0.383, 
p < 0.001; r = 0.300, p = 0.001) [15]. When CHA2DS2-
VASc score is modified by adding hyperlipidemia (H) and 
smoking (S), a stronger and significant correlation was 
found between CHA2DS2-VASc-HS score and Gensini 
score (r = 0.813, p < 0.001) [21]. Similar to this research, 
CHA2DS2-VASc-HSF also has a stronger and significant 
correlation with the severity of CAD measured by syntax 
score in NSTEMI patients compared to CHADS2 and 
CHA2DS2-VASc [22]. This suggested that CHA2DS2-
VASc-HSF score has a superior association with CAD 
severity compared to CHADS2 and CHA2DS2-VASc score.
We investigated whether the CHADS2-VASc-
HSF scores could aid clinicians to predict the patient 
who has higher odds of severe CAD, which need 
immediate diagnosis and treatments. This research 
showed that CHA2DS2-VASc-HSF has the highest odd 
Table 5: Pairwise comparison between receiver operating characteristic curves
Variables Differences between areas SE 95% CI Z- Statistic p-value
CHADS2 and CHA2DS2-VASc 0.0496 0.0227 0.0052–0.941 2.190 0.028
CHADS2 and CHA2DS2-VASc-HSF 0.154 0.0320 0.0914–0.217 4.819 ≤0.001
CHA2DS2-VASc and CHA2DS2-VASc-HSF 0.105 0.0255 0.0546–0.154 4.105 ≤0.001
SE: Standard error; CI: Confidence interval.
Discussion
The major findings of this research were: (1) 
CHA2DS2-VASc-HSF score was significantly increased 
both mild and severe CAD patients, (2) the CHADS2, 
Table 2: Spearman’s correlations between various 
independent variables with CAD Gensini score
Variables* Correlation coefficient (r)
Age (years) 0.276**
FBG (mg/dL) 0.180*
Ureum (mg/dL) 0.232**
Creatinine (mg/dL) 0.204**
WBC 0.236**
Ejection fraction (%) ‒0.215**
CHA2DS2 0.315**
CHA2DS2-VASc 0.395**
CHA2DS2-VASc-HSF 0.612**
*Significant correlation at p<0.05, **Significant correlation at p<0.01. FBG: Fasting blood glucose; 
WBC: White blood cells.
CHA2DS2-VASc, and CHA2DS2-VASc-HSF scores have 
positive and significant correlation with CAD severity 
measured by Gensini score, (3) CHADS2, CHA2DS2-VASc, 
Table 3: Univariate regression analysis for the predictors of 
severe CAD
Variables Odds ratio 95% CI p-value
Age (years) 1.036 1.007–1.066 0.013
SBP (mmHg) 1.003 0.992–1.015 0.585
DBP (mmHg) 1.015 0.990–1.042 0.242
BMI (kg/m2) 1.016 0.933–1.106 0.721
Hb (g/dL) 1.072 0.861–1.335 0.551
WBC (cells/µL) 1.000 1.000–1.000 0.676
HCT (%) 0.995 0.899–1.102 0.929
Platelet (× 103 cells/µL) 1.000 1.000–1.000 0.615
FBG (mg/dL) 1.009 1.001–1.017 0.024
Ureum (mg/dL) 1.103 1.045–1.164 ≤0.001
Creatinine (mg/dL) 5.000 1.756–14.233 0.005
Ejection fraction (%) 0.390 0.059–2.563 0.474
CHA2DS2 score 1.834 1.304–2.580 ≤0.001
CHA2DS2-VASc score 1.962 1.455–2.644 ≤0.001
CHA2DS2-VASc-HSF score 2.716 1.996–3.696 ≤0.001
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index, Hb: Hemoglobin; 
WBC: White blood cells; HCT: Hematocrit; PT: Prothrombin time; APTT: Activated partial thromboplastin 
time; FBG: Fasting blood glucose.
and CHA2DS2-VASc-HSF are significant predictors for 
severe CAD, the highest odds ratio was found on the 
CHA2DS2-VASc-HSF score, and (4) CHA2DS2-VASc-
HSF was the best score to predict severe CAD with the 
cutoff point of ≥2.5.
Table 4: Multivariate regression analysis for the predictors of 
severe CAD
Variables Odds ratio 95% CI p-value
With CHADS2 score
Age (years) 1.017 0.985–1.049 0.298
FBG (mg/dL) 1.002 0.994–1.011 0.588
Ureum (mg/dL) 1.067 1.008–1.130 0.026
Creatinine (mg/dL) 2.828 0.893–8.960 0.077
CHADS2 Score 1.572 1.009–2.345 0.046
With CHA2DS2-VASc score
Age (years) 1.008 0.976–1.042 0.613
FBG (mg/dL) 1.002 0.994–1.010 0.601
Ureum (mg/dL) 1.065 1.006–1.129 0.032
Creatinine (mg/dL) 2.323 0.731–7.380 0.153
CHA2DS2-VASc score 1.569 1.098–2.240 0.013
With CHA2DS2-VASc-HSF score
Age (years) 0.997 0.962–1.033 0.871
FBG (mg/dL) 0.997 0.989–1.006 0.516
Ureum (mg/dL) 1.065 0.998–1.137 0.056
Creatinine (mg/dL) 1.511 0.421–5.419 0.527
CHA2DS2-VASc-HSF Score 2.540 1.794–3.595 0.002
FBG: Fasting blood glucose; CI: Confidence interval.
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ratio to predict the severe CAD compared to CHADS2 
and CHA2DS2-VASc. Previously, the CHADS2 score, 
as one of the rapid and very practical scores for risk 
stratification for thromboembolism, has also shown 
able to predict CAD in ischemic stroke patients [23]. 
The development of CHADS2 into CHA2DS2-VASc 
score also has been shown to have better predictive 
power for long-term mortality for patients with severe 
CAD [24]. This suggested that the improvement of 
CHA2DS2-VASc into CHA2DS2-VASc-HSF may provide 
a better prediction for the odds of having severe CAD.
The CHADS2 score is considered as one 
of the rapid, wide range, and very practical for risk 
stratification for thromboembolism, which was also 
developed to predict CAD in ischemic stroke patients 
[23]. CHA2DS2-VASc is the development of the 
CHADS2 score, which showed better predictive power 
for long-term mortality for patients with CAD [24]. 
When compared with TIMI, GRACE score, CHA2DS2-
VASc showed that the capability to predict severe 
CAD measured by syntax score [25]. Modification of 
CHA2DS2-VASc into CHA2DS2-VASc-HS score also has 
been shown to improve its predictive value for severe 
CAD compared to both CHADS2 into CHA2DS2-VASc 
with the sensitivity of 85.2% and specificity of 57.5% at 
the cutoff value of >2 [13]. In this research, modification 
of CHA2DS2-VASc into CHA2DS2-VASc-HSF score 
also showed a higher AUC area compared to both 
CHADS2 into CHA2DS2-VASc score with the sensitivity 
of 81.4% and specificity of 68.1% at the cutoff value of 
>2.5. CHA2DS2-VASc-HSF also shown to be the best 
scoring scheme for severe CAD prediction compared to 
CHADS2 and CHA2DS2-VASc score. This suggests that 
CHA2DS2-VASc-HSF score is a better scoring method 
which easily used by the physician to screen the patient 
with angina, which may require referral for coronary 
angiography and early treatment.
However, this study may yet to be generalized 
since it only involved a single-center as the source of 
data. This study also used consecutive samplings from 
all patients who were admitted for diagnostic coronary 
angiography. Hence, selection bias might occur. In the 
future, it is suggested to involve more cardiac center 
and stratify the sample based on several factors such 
as race and social status to ensure the validity of the 
score among various demographic characteristics.
Conclusions
The CHA2DS2-VASc-HSF score can predict 
the severe CAD with superior validity compared to 
CHADS2 and CHA2DS2-VASc score. Suggesting that 
CHA2DS2-VASc-HSF score may be recommended for 
primary care physicians to easily predict severe CAD 
and refer them earlier without additional costs.
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